Name (Synonyms) | Correlation | |
---|---|---|
drug98 | BNT162a1 Wiki | 1.00 |
drug99 | BNT162b1 Wiki | 1.00 |
drug180 | Cell therapy protocol 1 Wiki | 1.00 |
drug101 | BNT162c2 Wiki | 1.00 |
drug100 | BNT162b2 Wiki | 1.00 |
drug616 | Placebo Wiki | 0.10 |
Name (Synonyms) | Correlation | |
---|---|---|
D055371 | Acute Lung Injury NIH | 0.16 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.15 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.13 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Acute Respiratory Distress Syndrome (ARDS) is the major cause of death in the COVID-19 pandemic. In this trial, the safety and efficacy of Mesenchymal Stem Cells (MSC) for the treatment of ARDS in COVID-19 patients will be assessed.
Description: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Measure: Adverse events assessment Time: From baseline to day 28Description: Evaluation of Pneumonia Improvement
Measure: Blood oxygen saturation Time: From baseline to day 14Description: Number of days
Measure: Intensive care unit-free days Time: Up to day 8Description: Improvement of clinical symptoms including duration of fever, respiratory distress, pneumonia, cough, sneezing
Measure: Clinical symptoms Time: From baseline to day 14Description: increase in PaO2/FiO2 ratio from baseline to day 7
Measure: Respiratory efficacy Time: From baseline to day 7Description: Biochemical examination
Measure: Biomarkers concentrations in plasma Time: At baseline, 7, 14, 28 days after the first intervention